Comprehensive Analysis of GLP-1 Receptor Agonists: Mechanisms, Formulations, Safety, and Market Dynamics

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a transformative class of pharmaceuticals, profoundly reshaping the therapeutic landscape for type 2 diabetes mellitus (T2DM), obesity, and a spectrum of associated cardiometabolic and renal conditions. This comprehensive report offers an exhaustive analysis of GLP-1 receptor agonists, delving into their intricate physiological and pharmacological mechanisms of action, their expansive therapeutic effects extending far beyond conventional glycemic control, and the critical distinctions between various oral and injectable formulations. Furthermore, it scrutinizes their long-term safety profiles, explores a burgeoning array of emerging indications, and dissects the dynamic and intensely competitive pharmaceutical market. By synthesizing current scientific evidence and clinical insights, this report aims to provide a definitive understanding of the pivotal role GLP-1 receptor agonists play in modern medicine.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists marks a significant inflection point in the management of type 2 diabetes mellitus (T2DM) and obesity. Historically, T2DM management primarily focused on agents that either stimulated insulin secretion, reduced insulin resistance, or decreased hepatic glucose output. While effective in lowering blood glucose, many traditional therapies often carried risks of hypoglycemia, weight gain, or lacked demonstrable cardiovascular (CV) or renal benefits [1]. The rising global prevalence of T2DM and obesity, coupled with their significant contributions to cardiovascular disease, chronic kidney disease, and mortality, underscored an urgent need for more comprehensive therapeutic strategies [2].

Into this landscape, GLP-1 receptor agonists arrived, initially conceived as sophisticated glucose-lowering agents. Their development was rooted in the discovery of incretin hormones, particularly GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which are released from the gut in response to nutrient ingestion and amplify glucose-dependent insulin secretion [3]. The recognition of GLP-1’s rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) paved the way for two main therapeutic approaches: DPP-4 inhibitors that prevent GLP-1 breakdown, and GLP-1 receptor agonists that mimic and sustain the action of native GLP-1, being resistant to DPP-4 degradation.

What began as a targeted approach to glycemic control has since blossomed into a multifaceted therapeutic strategy. These agents have unequivocally demonstrated a remarkable array of benefits, including substantial and sustained weight reduction, robust cardiovascular protection evidenced by reductions in major adverse cardiovascular events (MACE), and significant nephroprotection, effectively slowing the progression of diabetic kidney disease [4]. The recent landmark approval of semaglutide (Ozempic/Wegovy) for reducing the progression of diabetic kidney disease, following the positive outcomes of the FLOW trial, further cements the expanding therapeutic breadth of this drug class [5].

Concurrently, the pharmaceutical industry has witnessed a paradigm shift with the development of oral GLP-1 receptor agonists, such as oral semaglutide (Rybelsus) and the investigational non-peptide orforglipron. These oral formulations aim to address the historical barrier of injectability, potentially enhancing patient adherence, broadening accessibility, and democratizing the utilization of GLP-1-based therapies across a wider patient population [6].

This report embarks on a comprehensive journey to dissect the GLP-1 receptor agonist class. It will meticulously explore their complex mechanisms of action at molecular and systemic levels, delineate the breadth of their therapeutic effects beyond simple glycemic modulation, compare and contrast the different formulation types, thoroughly examine their long-term safety and tolerability profiles, illuminate emerging indications extending beyond their initial scope, and analyze the intricate and rapidly evolving dynamics of the global pharmaceutical market that these agents now dominate.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Mechanisms of Action

GLP-1 receptor agonists exert their profound effects by mimicking the actions of the endogenous incretin hormone, glucagon-like peptide-1 (GLP-1). This hormone is a 30-amino acid peptide, primarily secreted by enteroendocrine L-cells located in the distal ileum and colon, in response to nutrient ingestion [7]. Upon release, native GLP-1 has a very short half-life of approximately 1-2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists are designed to be resistant to DPP-4 degradation, thereby achieving sustained GLP-1 receptor activation and prolonged therapeutic effects [8].

2.1 GLP-1 Receptor Activation and Intracellular Signaling

The GLP-1 receptor (GLP-1R) is a G-protein coupled receptor (GPCR) belonging to the class B (secretin-like) family. It is widely expressed throughout the body, including pancreatic beta and alpha cells, the brain (hypothalamus, brainstem), stomach, intestines, heart, kidney, and adipose tissue [9]. Upon binding of GLP-1 receptor agonists, the receptor undergoes a conformational change, leading to the activation of stimulatory G proteins (Gαs). This activation, in turn, stimulates adenylyl cyclase, resulting in an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP then activates protein kinase A (PKA) and Epac2 (exchange protein activated by cAMP 2), which are key mediators of the downstream signaling cascade [10].

2.2 Pancreatic Effects

2.2.1 Enhanced Glucose-Dependent Insulin Secretion

This is a cornerstone effect of GLP-1 receptor agonists. In the presence of elevated glucose levels, GLP-1R activation in pancreatic beta cells leads to a robust increase in insulin secretion. The mechanism involves:

• Closure of KATP channels: PKA and Epac2 activation leads to the closure of ATP-sensitive potassium (KATP) channels, resulting in beta-cell membrane depolarization [11].
• Opening of voltage-gated calcium channels: Depolarization opens voltage-gated calcium channels, allowing an influx of Ca2+ into the beta cell.
• Insulin granule exocytosis: The rise in intracellular Ca2+ is a potent trigger for the exocytosis of insulin-containing granules, leading to increased insulin release [12].

Crucially, this effect is glucose-dependent, meaning that GLP-1 receptor agonists primarily stimulate insulin secretion when blood glucose levels are high, thereby minimizing the risk of hypoglycemia when glucose levels are normal or low [13]. Beyond acute insulin release, long-term GLP-1R activation has been shown in preclinical studies to promote beta-cell proliferation, inhibit beta-cell apoptosis, and improve overall beta-cell function and mass, though the extent of these effects in humans remains an area of ongoing research [14].

2.2.2 Inhibition of Glucagon Secretion

GLP-1 receptor agonists also exert a significant effect on pancreatic alpha cells, suppressing inappropriate glucagon secretion. Glucagon, produced by alpha cells, elevates blood glucose by promoting hepatic glucose production (glycogenolysis and gluconeogenesis). By reducing glucagon levels, especially in the postprandial state, GLP-1 receptor agonists contribute to lower blood glucose [15]. This inhibition is thought to be mediated by both direct GLP-1R activation on alpha cells and indirectly via increased intra-islet insulin and somatostatin levels, which are known to inhibit glucagon secretion [16].

2.3 Gastrointestinal Effects

2.3.1 Delayed Gastric Emptying

GLP-1 receptor agonists significantly slow the rate at which food empties from the stomach into the small intestine. This effect contributes to improved postprandial glucose control by reducing the rate of glucose absorption and blunting the postprandial glucose excursion [17]. Furthermore, delayed gastric emptying contributes to satiety, as it prolongs the feeling of fullness and distention, reducing the urge to consume more food [18]. This mechanism is crucial for the weight-loss benefits observed with these agents.

2.3.2 Promotion of Satiety and Reduced Food Intake

GLP-1 receptors are present in various regions of the brain involved in appetite regulation, including the hypothalamus (arcuate nucleus) and brainstem (nucleus of the solitary tract, area postrema) [19]. GLP-1 receptor agonists activate these neural pathways, leading to a reduction in appetite, increased feelings of satiety, and a decrease in overall food consumption. This central effect, combined with delayed gastric emptying, is a primary driver of the significant weight loss observed in patients using these medications [20]. The pathways involve modulation of neuropeptide Y (NPY), agouti-related peptide (AgRP), proopiomelanocortin (POMC), and cocaine- and amphetamine-regulated transcript (CART) neurons in the arcuate nucleus, shifting the balance towards reduced food intake and increased energy expenditure. Vagal afferent pathways also play a role in transmitting satiety signals from the gut to the brain [21].

2.4 Beyond Glycemic Control: Pleiotropic Effects

The widespread distribution of GLP-1 receptors across various organ systems underlies the pleiotropic benefits observed with GLP-1 receptor agonists, extending their utility beyond mere glycemic control.

2.4.1 Cardiovascular System

GLP-1 receptors are found in the heart (atrial and ventricular myocardium, cardiac vessels), endothelium, and smooth muscle cells. Activation of these receptors contributes to cardiovascular protection through multiple mechanisms:

• Blood Pressure Reduction: Directly by promoting natriuresis (sodium excretion) and vasodilation, and indirectly through weight loss [22].
• Improved Endothelial Function: Enhancing nitric oxide bioavailability and reducing oxidative stress [23].
• Anti-atherosclerotic Effects: Reducing inflammation, improving lipid profiles (e.g., lowering triglycerides), and inhibiting foam cell formation in arterial walls [24].
• Direct Myocardial Effects: Some evidence suggests improved myocardial function, reduced myocardial stunning, and enhanced cardiac glucose uptake, particularly in ischemic conditions, potentially leading to cardioprotection [25].
• Reduced Inflammatory Markers: Lowering circulating inflammatory cytokines which contribute to atherosclerosis.

2.4.2 Renal System

GLP-1 receptors are present in various parts of the kidney, including glomeruli, renal tubules, and afferent arterioles. Their activation contributes to nephroprotection through:

• Reduction in Glomerular Hyperfiltration: Modulating afferent arteriolar tone and reducing intraglomerular pressure, which is beneficial in diabetic kidney disease [26].
• Natriuresis: Directly increasing sodium excretion, contributing to blood pressure reduction.
• Anti-inflammatory and Anti-fibrotic Effects: Mitigating renal inflammation and fibrosis, key drivers of kidney disease progression [27].
• Improved Glycemic and Hemodynamic Control: Indirectly, by improving blood glucose, reducing body weight, and lowering blood pressure, which all alleviate stress on the kidneys.

2.4.3 Other Potential Systemic Effects

Emerging research suggests GLP-1 receptor agonists may also have neuroprotective effects, reduce hepatic steatosis, and possess general anti-inflammatory properties, further expanding their potential therapeutic applications beyond their established indications [28, 29].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Therapeutic Effects Beyond Glycemic Control

While initially recognized for their potent glucose-lowering capabilities, GLP-1 receptor agonists have unequivocally demonstrated a remarkable array of benefits that extend far beyond glycemic control, fundamentally altering their perception and application in clinical practice. These pleiotropic effects, particularly in weight management, cardiovascular outcomes, and renal protection, have positioned them as cornerstone therapies for a broader spectrum of cardiometabolic diseases.

3.1 Weight Reduction

One of the most striking and clinically significant therapeutic effects of GLP-1 receptor agonists is their profound ability to induce substantial and sustained weight loss. This effect is primarily mediated through two complementary mechanisms: a reduction in caloric intake due to enhanced satiety and a decrease in gastric emptying rate. Clinical trials have consistently demonstrated that GLP-1 receptor agonists can lead to significant reductions in body weight, making them invaluable tools in the management of overweight and obesity, irrespective of a diabetes diagnosis [30].

For instance, the STEP (Semaglutide Treatment Effect in People with Obesity) program stands as a landmark series of clinical trials specifically investigating semaglutide for weight management. In STEP 1, a pivotal phase 3 trial, participants without diabetes but with overweight or obesity receiving once-weekly subcutaneous semaglutide 2.4 mg achieved an average body weight reduction of approximately 14.9% from baseline, compared to 2.4% with placebo over 68 weeks [31]. This magnitude of weight loss is clinically meaningful and approaches the efficacy observed with bariatric surgery in some individuals, often leading to improvements in obesity-related comorbidities such as sleep apnea, dyslipidemia, and hypertension. Other GLP-1 RAs also contribute to weight loss, albeit to varying degrees; for example, liraglutide 3.0 mg (Saxenda) demonstrated an average weight loss of 5-10% in trials [32].

The weight loss induced by GLP-1 receptor agonists is predominantly from fat mass, with preservation of lean muscle mass, which is a desirable outcome. The sustained nature of the weight reduction observed in longer-term studies underscores their utility in chronic weight management [33]. The implications of this weight loss extend beyond cosmetic benefits, significantly reducing the mechanical and metabolic burdens associated with obesity, and contributing to the overall cardiometabolic improvements seen with these agents.

3.2 Cardiovascular Benefits

The demonstration of cardiovascular (CV) safety, and subsequently CV benefit, has been a defining characteristic of the GLP-1 receptor agonist class. Following regulatory requirements for new diabetes medications to demonstrate CV safety, a series of large-scale, placebo-controlled cardiovascular outcome trials (CVOTs) were conducted, which not only confirmed safety but also revealed significant reductions in major adverse cardiovascular events (MACE) [34].

Key CVOTs include:

• LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results): This trial, involving over 9,000 patients with T2DM at high CV risk, demonstrated that liraglutide significantly reduced the composite endpoint of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke by 13% compared to placebo over a median follow-up of 3.8 years [35]. Notably, liraglutide also significantly reduced CV death by 22% and all-cause mortality by 15%.
• SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes): This trial assessed once-weekly subcutaneous semaglutide in over 3,200 T2DM patients at high CV risk. Semaglutide reduced the composite MACE endpoint by a significant 26% compared to placebo over 2.1 years [36]. The benefit was primarily driven by reductions in non-fatal stroke (39% reduction) and non-fatal MI (26% reduction).
• PIONEER 6 (Peptide InnOvatioN for the treatment of Type 2 Diabetes; Oral Semaglutide): This trial specifically evaluated the CV safety of oral semaglutide in over 3,100 T2DM patients with established CV disease or high CV risk. While primarily a safety trial, oral semaglutide demonstrated a non-inferiority for MACE and a numerically lower MACE rate (hazard ratio 0.79), consistent with the injectable formulation’s benefits [37].
• REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes): This trial investigated dulaglutide in over 9,900 T2DM patients, many of whom had CV risk factors but not established CV disease. Dulaglutide significantly reduced MACE by 12% over a median follow-up of 5.4 years, showing benefit in a broader population [38].
• EXSCEL (Exenatide Study of Cardiovascular Event Lowering): This trial evaluated once-weekly exenatide in over 14,700 T2DM patients. Exenatide demonstrated CV safety (non-inferiority for MACE) but did not show superiority for the primary composite MACE endpoint, suggesting some heterogeneity within the class [39].

The mechanisms underlying these CV benefits are multifaceted and include improvements in traditional CV risk factors (e.g., blood pressure reduction, weight loss, improved lipid profiles, glycemic control), direct effects on vascular function (e.g., improved endothelial function, reduced arterial stiffness), anti-inflammatory and anti-atherosclerotic effects, and potentially direct protective effects on the myocardium (e.g., improved myocardial metabolism, reduction in ischemia/reperfusion injury) [40]. These extensive CVOTs have led to professional guidelines recommending the use of GLP-1 receptor agonists in patients with T2DM and established atherosclerotic cardiovascular disease or high CV risk, often as a preferred second-line agent after metformin [41].

3.3 Nephroprotection

Beyond their glycemic and cardiovascular effects, GLP-1 receptor agonists have emerged as potent agents in the field of nephroprotection, particularly for patients with diabetic kidney disease (DKD). DKD is a leading cause of end-stage renal disease, and effective therapies to slow its progression are critically needed [42]. The nephroprotective effects of GLP-1 receptor agonists are attributed to a combination of direct renal actions and indirect benefits from improved metabolic control.

Evidence from CVOTs initially hinted at these renal benefits. Most GLP-1 RA CVOTs included renal composite endpoints, typically defined as new-onset macroalbuminuria, sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), or renal death. For instance, in LEADER, liraglutide reduced the risk of the composite renal microvascular outcome by 22% [35]. In SUSTAIN-6, semaglutide reduced the risk of new or worsening nephropathy by 36% [36]. Similarly, REWIND showed dulaglutide reduced the composite renal outcome by 27% [38]. These consistent findings across multiple agents suggested a class effect for renal benefit.

The recent FLOW (Kidney Outcomes With Once-Weekly Semaglutide in Type 2 Diabetes and Chronic Kidney Disease) trial, a dedicated renal outcomes study, provided definitive evidence for semaglutide’s nephroprotective effects. In over 3,500 patients with T2DM and CKD, semaglutide significantly reduced the risk of the primary composite renal outcome (sustained eGFR decline of ≥50%, ESRD, renal death, or CV death) by 24% compared to placebo over a mean follow-up of 3.4 years [5]. This trial demonstrated a clear and significant reduction in kidney disease progression and major adverse kidney and cardiovascular events, independent of glucose-lowering effects, reinforcing the direct renal benefits.

Proposed mechanisms for nephroprotection include:

• Hemodynamic effects: Reduction in intraglomerular pressure by modulating afferent arteriolar tone and promoting natriuresis, alleviating hyperfiltration [4].
• Anti-inflammatory and Anti-fibrotic actions: Directly mitigating inflammation and fibrosis in renal cells, which are critical drivers of CKD progression [27].
• Improved endothelial function: Enhancing the health of renal microvasculature.
• Reduction in albuminuria: Consistently observed reductions in urinary albumin-to-creatinine ratio (UACR), a marker of kidney damage [42].
• Indirect effects: Through significant improvements in glycemic control, weight loss, and blood pressure reduction, all of which lessen the burden on the kidneys [26].

These robust data solidify the role of GLP-1 receptor agonists as essential components in the comprehensive management of T2DM patients, particularly those with or at risk of developing kidney disease, complementing existing renoprotective strategies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Formulations: Oral vs. Injectable

The mode of administration for GLP-1 receptor agonists has been a significant factor in their clinical adoption and patient acceptance. Historically, all agents in this class were administered via subcutaneous injection. However, recent advancements have introduced oral formulations, aiming to enhance convenience and adherence.

4.1 Injectable Formulations

Injectable GLP-1 receptor agonists have been the cornerstone of therapy since the first agent, exenatide (Byetta), was approved in 2005. This category includes a range of drugs with varying half-lives, dictating their dosing frequency:

• Short-acting agents: Exenatide (Byetta) is administered twice daily, and liraglutide (Victoza) is administered once daily. These agents provide more pronounced postprandial glucose control and gastric emptying effects due to their peak concentrations aligning with meals [43]. Liraglutide 3.0 mg (Saxenda) is specifically approved for chronic weight management.
• Long-acting agents: These formulations, engineered to have extended half-lives, allow for less frequent dosing, typically once weekly. Examples include exenatide extended-release (Bydureon), dulaglutide (Trulicity), and semaglutide (Ozempic/Wegovy) [44]. Their sustained action provides more consistent glycemic control throughout the day and week, and they generally achieve greater weight loss than short-acting agents. Dulaglutide and semaglutide have demonstrated significant cardiovascular benefits in their respective CVOTs, making them preferred choices for patients with established cardiovascular disease or high risk.

Advantages of Injectable Formulations:
* Established Efficacy: Decades of clinical experience and robust evidence from numerous large-scale clinical trials (CVOTs, weight management trials) underpin their efficacy across glycemic, weight, cardiovascular, and renal outcomes.
* Potency: Generally highly potent in achieving desired therapeutic effects due to direct systemic absorption.
* Predictable Pharmacokinetics: Subcutaneous absorption typically provides consistent drug levels.

Disadvantages of Injectable Formulations:
* Patient Reluctance: The necessity for injections can be a significant psychological and practical barrier for many patients, leading to reduced adherence or initiation rates [45].
* Injection Site Reactions: Localized reactions such as pain, redness, or swelling can occur, though typically mild.
* Storage: Some injectable formulations require refrigeration.

4.2 Oral Formulations

The development of oral GLP-1 receptor agonists represents a major advancement, addressing the convenience barrier associated with injectables. This innovation leverages different pharmacological strategies to achieve systemic absorption of large peptide molecules or develops non-peptide small molecules that can be orally bioavailable.

4.2.1 Oral Semaglutide (Rybelsus)

Oral semaglutide (Rybelsus), approved in 2019, was the first oral GLP-1 receptor agonist. It is a co-formulation of semaglutide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) [46]. SNAC facilitates the absorption of the peptide semaglutide across the gastric mucosa by locally increasing its solubility and protecting it from enzymatic degradation. To ensure optimal absorption, oral semaglutide must be taken on an empty stomach with a small amount of water (no more than 120 mL) at least 30 minutes before the first food, drink, or other oral medications of the day [46].

Advantages of Oral Semaglutide:
* Convenience: Oral administration significantly improves patient preference and potentially adherence compared to injections.
* Comparable Efficacy: Clinical trials (the PIONEER program) demonstrated that oral semaglutide is effective in lowering HbA1c and inducing weight loss, with efficacy comparable to injectable GLP-1 RAs, albeit with careful adherence to dosing instructions [47].
* Cardiovascular Safety: PIONEER 6 trial confirmed its cardiovascular safety profile, consistent with the injectable formulation [37].

Disadvantages of Oral Semaglutide:
* Strict Dosing Requirements: The need for fasting and specific water volume can be inconvenient and challenging for some patients, potentially impacting real-world effectiveness if not strictly adhered to [46].
* Absorption Variability: Absorption can be variable if dosing instructions are not followed precisely.
* Gastrointestinal Side Effects: Similar to injectables, GI side effects are common, particularly during dose escalation.

4.2.2 Orforglipron

Orforglipron, developed by Eli Lilly, represents a new generation of oral GLP-1 receptor agonists. Unlike semaglutide, which is a peptide, orforglipron is a small molecule, non-peptide GLP-1 receptor agonist [48]. This distinction is crucial because small molecules generally have better oral bioavailability and less complex manufacturing processes compared to peptides. Orforglipron is taken once daily, without the strict fasting requirements of oral semaglutide.

Advantages of Orforglipron:
* True Oral Bioavailability: Being a non-peptide small molecule, it inherently possesses properties conducive to oral absorption, eliminating the need for absorption enhancers like SNAC.
* Dosing Flexibility: The absence of strict fasting or water volume requirements makes it potentially more convenient and easier for patients to incorporate into their daily routines [49].
* Efficacy and Weight Loss: Phase 2 clinical trials have shown significant reductions in HbA1c and body weight, comparable to or even exceeding existing injectable GLP-1 RAs [50]. For example, a phase 2 trial demonstrated a mean HbA1c reduction of up to 2.1% and weight loss of up to 14.7% at the highest dose after 26 weeks.
* Competitive Landscape: Its oral nature and promising efficacy position it as a strong competitor to existing injectable and oral GLP-1 RAs, particularly for patients hesitant about injections.

Future Outlook for Oral Formulations:
The development of oral non-peptide GLP-1 receptor agonists like orforglipron and others in pipelines (e.g., from Pfizer) signifies a major shift towards making these highly effective therapies more accessible and patient-friendly. This could profoundly impact patient adherence, expand the market reach, and potentially democratize access to these life-changing medications, particularly for obesity management [51]. The convenience of a pill could accelerate the adoption of GLP-1 based therapies, particularly in primary care settings where injections might be perceived as a barrier.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Long-Term Safety Profiles

GLP-1 receptor agonists are generally considered safe and well-tolerated medications, especially given their glucose-dependent mechanism of action, which inherently reduces the risk of hypoglycemia compared to sulfonylureas or insulin. However, like all medications, they are associated with certain adverse effects, primarily gastrointestinal, and have been subject to scrutiny regarding rare but serious potential risks [52].

5.1 Gastrointestinal Adverse Events (GI AEs)

These are the most common side effects and are typically mild-to-moderate, transient, and dose-dependent. They occur more frequently during the initial titration phase as the body adjusts to the drug’s effects, particularly delayed gastric emptying and central effects on appetite centers. Common GI AEs include:

• Nausea: Reported in 20-50% of patients, often improving over time [53].
• Vomiting: Less frequent than nausea, affecting 10-20% of patients.
• Diarrhea or Constipation: Occurring in 10-20% of patients, with the specific pattern varying between individuals and agents.
• Abdominal Pain: Also reported, typically mild.

Management of GI AEs: Gradual dose escalation, as per prescribing information, is crucial to minimize these side effects. Taking the medication with meals (for some agents, where not contraindicated) or adjusting meal size and composition can also help [54]. Persistent or severe GI symptoms may necessitate dose reduction or discontinuation.

5.2 Pancreatitis

Early post-marketing reports and some observational studies raised concerns about an increased risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors. However, large-scale clinical trials and meta-analyses, particularly the dedicated cardiovascular outcome trials, have not consistently demonstrated a statistically significant increase in the risk of acute pancreatitis compared to placebo or other diabetes medications [55, 56]. For example, a meta-analysis of 116 randomized clinical trials involving various GLP-1 receptor agonists found no increased risk of pancreatitis [57]. While a definitive causal link has not been established, a cautious approach is recommended. GLP-1 receptor agonists are generally contraindicated in patients with a history of pancreatitis, and if pancreatitis is suspected, the medication should be promptly discontinued [52]. The mechanism by which GLP-1 receptor agonists might theoretically influence pancreatitis risk is not fully understood, but it could involve effects on pancreatic exocrine secretion or inflammation.

5.3 Thyroid C-cell Tumors and Medullary Thyroid Carcinoma (MTC)

Concerns regarding thyroid C-cell tumors and MTC arose from preclinical studies where GLP-1 receptor agonists caused a dose-dependent increase in C-cell hyperplasia and MTC in rodents (rats and mice) [58]. C-cells are neuroendocrine cells in the thyroid gland that produce calcitonin, and they express GLP-1 receptors in rodents. However, human C-cells typically express very few or no GLP-1 receptors, and MTC is a rare form of thyroid cancer [59].

Extensive clinical experience and large CVOTs in humans have not shown an increased risk of MTC or C-cell hyperplasia in patients treated with GLP-1 receptor agonists. Long-term observational studies and post-marketing surveillance data have also not established a causal link [60]. Despite this, the product labels for all GLP-1 receptor agonists include a boxed warning regarding the risk of C-cell tumors based on rodent data. They are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a genetic condition predisposing to MTC [52]. Routine monitoring of serum calcitonin (a tumor marker for MTC) is not generally recommended due to its low predictive value and high false-positive rates [61].

5.4 Diabetic Retinopathy Complications

An unexpected finding emerged from the SUSTAIN-6 trial, where semaglutide was associated with a higher incidence of diabetic retinopathy complications (e.g., vitreous hemorrhage, blindness) compared to placebo [36]. This increased risk was not observed with other GLP-1 receptor agonists in their respective CVOTs (e.g., LEADER, REWIND, EXSCEL) [62]. The proposed mechanism for this effect is thought to be related to the rapid improvement in glycemic control, rather than a direct drug effect. Rapid glucose lowering, regardless of the agent used (e.g., intensive insulin therapy), has been linked to transient worsening of retinopathy, particularly in patients with pre-existing retinopathy [63]. Therefore, close monitoring of diabetic retinopathy is recommended for patients initiating semaglutide, especially those with pre-existing retinopathy. This effect is considered a class effect of very rapid glucose reduction, not specific to semaglutide itself, though it was most clearly observed in this trial due to its design and the potency of semaglutide’s glucose-lowering effect.

5.5 Other Potential Concerns

• Gallbladder-related disorders: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported, particularly with rapid weight loss, a known risk factor for gallstone formation [64]. Patients experiencing significant weight loss with GLP-1 RAs should be monitored for symptoms of gallbladder disease.
• Acute Kidney Injury (AKI): While GLP-1 RAs generally have renoprotective effects, rare cases of AKI have been reported, typically in the context of severe gastrointestinal adverse events (e.g., vomiting, diarrhea) leading to dehydration and volume depletion. Patients should be advised to maintain adequate hydration [52].
• Hypoglycemia: The risk of hypoglycemia is low when GLP-1 receptor agonists are used as monotherapy or in combination with metformin or thiazolidinediones, as their insulin-secreting effect is glucose-dependent. However, the risk increases when co-administered with sulfonylureas or insulin, necessitating dose adjustments of these concomitant medications [65].

In summary, while GLP-1 receptor agonists possess a favorable safety profile, particularly in light of their profound therapeutic benefits, clinicians must be aware of and monitor for these potential adverse effects. The benefits in T2DM, obesity, and cardiovascular/renal protection generally outweigh the risks for most eligible patients, especially when appropriate patient selection and monitoring strategies are employed.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Emerging Indications

The profound impact of GLP-1 receptor agonists on metabolism, appetite, and organ systems has spurred extensive research into their potential utility beyond their established indications of T2DM, obesity, and related cardiovascular/renal benefits. A growing body of evidence suggests their promise in managing a diverse range of conditions, highlighting the multifaceted nature of GLP-1 receptor signaling.

6.1 Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

NAFLD, encompassing a spectrum from simple hepatic steatosis to NASH (which can progress to cirrhosis and hepatocellular carcinoma), is strongly associated with obesity, insulin resistance, and T2DM [66]. GLP-1 receptor agonists offer a compelling therapeutic strategy for NAFLD/NASH through several mechanisms:

• Weight Loss: Significant weight reduction, particularly of visceral fat, directly contributes to reduced hepatic fat accumulation [67].
• Improved Insulin Sensitivity: Leading to better hepatic glucose and lipid metabolism.
• Direct Hepatic Effects: GLP-1 receptors are present in the liver. GLP-1 RAs have been shown to reduce hepatic steatosis, decrease liver enzymes (ALT, AST), and potentially reduce liver inflammation and fibrosis [68]. For example, in the NASH trial with semaglutide, a phase 2 study, once-daily semaglutide led to a higher rate of NASH resolution without worsening of fibrosis compared to placebo [69].
• Reduced Inflammation and Oxidative Stress: Mitigating the drivers of liver damage and progression to NASH.

GLP-1 RAs are increasingly recognized as a viable option for improving liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, the new nomenclature for NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH, for NASH), particularly when accompanied by obesity or T2DM. This area is a significant focus of ongoing clinical trials.

6.2 Polycystic Ovary Syndrome (PCOS)

PCOS is a common endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. It is frequently associated with insulin resistance, obesity, and an increased risk of T2DM and cardiovascular disease [70]. GLP-1 receptor agonists are being investigated for their potential to address the metabolic aspects of PCOS:

• Weight Management: Given the high prevalence of obesity in PCOS patients, weight loss induced by GLP-1 RAs can significantly improve metabolic and reproductive outcomes [71].
• Improved Insulin Sensitivity: Reducing insulin resistance, a key pathogenic factor in PCOS, which can ameliorate hyperandrogenism and improve menstrual regularity [72].
• Reduction in Androgen Levels: Indirectly through improved insulin sensitivity and weight loss, and potentially through direct effects on ovarian steroidogenesis.

While evidence is still emerging from smaller studies, GLP-1 RAs offer a promising therapeutic avenue for managing the metabolic complications of PCOS, particularly for overweight or obese individuals unresponsive to lifestyle interventions [73].

6.3 Addiction Disorders

The influence of GLP-1 receptor agonists on brain reward pathways has opened avenues for their exploration in treating various addiction disorders, including alcohol use disorder, nicotine dependence, and potentially even food addiction (beyond obesity management) [74]. GLP-1 receptors are expressed in brain regions involved in reward, motivation, and executive function, such as the ventral tegmental area (VTA), nucleus accumbens, and prefrontal cortex [75].

Preclinical studies have shown that GLP-1 RAs can reduce alcohol intake, suppress nicotine self-administration, and decrease the rewarding effects of opioids and stimulants. The proposed mechanisms include:

• Modulation of Dopamine Pathways: Affecting the mesolimbic dopamine system, which is central to the rewarding effects of addictive substances [75].
• Reduced Craving: Decreasing the desire or urge to consume addictive substances.
• Stress and Anxiety Reduction: Indirectly influencing stress-related pathways that can trigger relapse.

Early clinical trials and anecdotal reports are beginning to emerge, suggesting that GLP-1 RAs could offer a novel pharmacotherapy for addiction, particularly in comorbid obesity/T2DM patients [76]. This area of research is nascent but holds significant promise.

6.4 Neurodegenerative Diseases (e.g., Alzheimer’s, Parkinson’s)

An intriguing area of research is the potential neuroprotective effects of GLP-1 receptor agonists, particularly in neurodegenerative conditions like Alzheimer’s disease (AD) and Parkinson’s disease (PD). The brain is a significant site of GLP-1 receptor expression, and growing evidence links metabolic dysfunction (e.g., insulin resistance, type 2 diabetes) to an increased risk and progression of neurodegenerative disorders [77].

Proposed mechanisms include:

• Improved Brain Insulin Signaling: Addressing cerebral insulin resistance, often referred to as ‘type 3 diabetes’ in the context of AD.
• Anti-inflammatory Effects: Reducing neuroinflammation, a hallmark of neurodegeneration [78].
• Anti-apoptotic and Neurotrophic Effects: Protecting neurons from damage and promoting neuronal survival.
• Mitochondrial Function: Enhancing mitochondrial bioenergetics in the brain [79].
• Reduction of Amyloid-Beta and Tau Pathology: Some preclinical studies suggest direct effects on the pathological hallmarks of AD.

Clinical trials are underway to investigate the efficacy of GLP-1 RAs, such as liraglutide and semaglutide, in patients with early AD or PD, with preliminary results showing some promise in slowing cognitive decline or motor progression in select populations [80]. While definitive evidence is still awaited, this represents a fascinating and potentially impactful new frontier for GLP-1 based therapies.

6.5 Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF is a growing public health concern, characterized by normal or near-normal left ventricular ejection fraction but impaired ventricular relaxation and increased stiffness. It is frequently associated with obesity, T2DM, hypertension, and chronic kidney disease [81]. The STEP-HFpEF trial investigated the effect of semaglutide 2.4 mg once weekly in obese (BMI ≥30 kg/m²) patients with HFpEF, regardless of diabetes status [82].

The trial demonstrated that semaglutide led to significant improvements in HF-related symptoms (measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, KCCQ-CSS), greater reduction in body weight, and improvements in exercise function (6-minute walk distance) compared to placebo. These benefits were observed in both diabetic and non-diabetic individuals with obesity and HFpEF. The primary mechanism is thought to be related to the substantial weight loss, which reduces cardiac load, improves myocardial mechanics, and mitigates systemic inflammation associated with obesity-related HFpEF. This positions GLP-1 RAs as a potential therapeutic option for improving quality of life and functional capacity in this challenging patient population [82].

These emerging indications underscore the versatility and broad therapeutic potential of GLP-1 receptor agonists, highlighting their evolution from niche diabetes drugs to agents with widespread metabolic and systemic benefits, potentially addressing multiple unmet medical needs.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Pharmaceutical Market Dynamics

The pharmaceutical market for GLP-1 receptor agonists has undergone an explosive transformation, transitioning from a niche segment for diabetes management to one of the most significant and rapidly expanding therapeutic areas, driven by their profound efficacy in weight loss and proven cardiovascular and renal benefits. This shift has ignited intense competition, substantial investments in research and development, and complex pricing and access debates.

7.1 Market Size and Growth Trajectory

The global GLP-1 receptor agonist market was valued at several billion USD in recent years and is projected to experience exponential growth, reaching tens of billions of USD within the next decade [83]. This unprecedented growth is primarily fueled by:

• Increasing Prevalence of T2DM and Obesity: The global epidemics of T2DM and obesity continue to drive demand for effective treatments.
• Expansion of Indications: Approvals for obesity (e.g., semaglutide as Wegovy, liraglutide as Saxenda) and the demonstrated CV/renal benefits have significantly broadened the eligible patient population beyond T2DM.
• High Clinical Efficacy: The superior HbA1c lowering, substantial weight loss, and proven organ protection offered by these agents position them as highly desirable therapies.
• Patient and Physician Demand: Growing awareness among patients and clinicians regarding the comprehensive benefits.

7.2 Key Players and Competitive Landscape

The GLP-1 receptor agonist market is currently dominated by two major pharmaceutical giants:

• Novo Nordisk: A pioneer in the field, Novo Nordisk holds a commanding market share with a portfolio including liraglutide (Victoza for T2DM, Saxenda for obesity), and semaglutide (Ozempic for T2DM, Wegovy for obesity, Rybelsus as the oral formulation) [6]. Their strategic investments in large-scale CVOTs and dedicated obesity trials have solidified their leadership.
• Eli Lilly and Company: Eli Lilly is a formidable competitor, primarily with dulaglutide (Trulicity) for T2DM and cardiovascular risk reduction. More recently, Eli Lilly launched tirzepatide (Mounjaro for T2DM, Zepbound for obesity), a novel dual GIP/GLP-1 receptor agonist [84]. While not a pure GLP-1 RA, its superior efficacy in both glycemic control and weight loss, leveraging both incretin pathways, positions it as a significant market disruptor and a direct competitor in the broader incretin-based therapy space. The development of the oral non-peptide GLP-1 RA, orforglipron, further demonstrates Eli Lilly’s aggressive pursuit of market leadership [48].

Other companies with active pipelines or existing, though smaller, market shares include AstraZeneca (Bydureon BCise – exenatide ER), and potentially future entrants with novel compounds or combination therapies [83].

Competitive Strategies and Trends:

• Oral vs. Injectable Formulations: The race for convenient oral formulations is a major competitive battleground, aiming to capture patients who are injection-averse. Oral semaglutide and orforglipron exemplify this trend.
• Next-Generation Agonists: Development of dual (e.g., GIP/GLP-1 like tirzepatide) or triple (e.g., GIP/GLP-1/Glucagon) receptor agonists represents the cutting edge, promising even greater efficacy [85]. These multi-agonist approaches aim to leverage synergistic effects of different hormonal pathways for enhanced metabolic benefits.
• Longer-Acting Formulations: Efforts continue to develop once-monthly or even less frequent injectable formulations to further improve patient convenience and adherence.
• Broader Indications: Companies are investing heavily in clinical trials to secure approvals for new indications (e.g., NASH, HFpEF, neurodegenerative diseases), expanding market opportunities beyond diabetes and obesity.
• Pricing and Reimbursement: The high cost of these therapies remains a critical challenge. Pharmaceutical companies navigate complex pricing strategies, health economic evaluations, and reimbursement negotiations with payers globally. Affordability is a major barrier to widespread access, leading to ongoing debates about value-based pricing and cost-effectiveness [86].
• Supply Chain Resilience: The unprecedented demand, particularly for weight-loss indications, has led to significant supply shortages for certain GLP-1 RAs (e.g., Wegovy) [87]. Companies are under pressure to rapidly scale up manufacturing to meet global demand, which impacts market availability and competition.

7.3 Access and Affordability Challenges

Despite their undeniable efficacy, the high cost of GLP-1 receptor agonists poses a significant barrier to widespread patient access. Monthly out-of-pocket costs can be substantial for patients without adequate insurance coverage, or for those whose insurance plans have restrictive formularies or high deductibles for these newer drug classes [86].

• Insurance Coverage: While coverage for T2DM is often more robust, coverage for obesity-specific indications remains variable and often depends on the payer, employer, and specific policy. This discrepancy creates inequities in access, particularly for the large population living with obesity without a diabetes diagnosis.
• Formulary Restrictions: Payers often implement prior authorization requirements, step therapy protocols, or limit access to patients meeting strict criteria (e.g., specific BMI thresholds, failed prior therapies, presence of comorbidities) [88].
• Cost-Effectiveness Debates: Health technology assessment bodies in various countries evaluate the cost-effectiveness of these drugs, influencing national reimbursement policies. The long-term cost savings associated with preventing CV events, kidney failure, and other comorbidities are part of this complex economic equation.

These market dynamics signify a period of rapid innovation and intense competition within the GLP-1 receptor agonist space. The emphasis is shifting towards therapies offering superior efficacy, greater convenience (oral options), and broader applications, while simultaneously grappling with the challenges of ensuring equitable patient access and managing unprecedented demand. The future will likely see further diversification of agents, including combination therapies, and continued pressure on pricing and reimbursement strategies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as one of the most profoundly transformative classes of medications in contemporary pharmacology, fundamentally reshaping the treatment paradigms for a constellation of cardiometabolic diseases. Their initial role as potent glucose-lowering agents in type 2 diabetes mellitus (T2DM) has expanded dramatically, now encompassing robust efficacy in chronic weight management, compelling cardiovascular protection, and significant nephroprotection, thereby addressing critical unmet needs in global health [30, 34, 42].

The intricate mechanisms of action, rooted in the mimicry of endogenous incretin hormone GLP-1, allow these agents to exert multifaceted systemic effects. These include glucose-dependent insulin secretion, suppression of glucagon, profound appetite regulation through central nervous system pathways, and significant delays in gastric emptying. Beyond these core mechanisms, their widespread receptor distribution underpins pleiotropic benefits on the heart, vasculature, and kidneys, contributing to their remarkable organ-protective qualities [9, 22, 26]. Landmark clinical trials, such as the STEP program for weight loss, and the comprehensive suite of cardiovascular outcome trials (LEADER, SUSTAIN-6, REWIND, PIONEER 6), alongside the pivotal FLOW renal outcomes trial, have meticulously documented these extensive benefits, establishing GLP-1 receptor agonists as cornerstone therapies for patients with T2DM, obesity, and associated comorbidities [31, 35, 36, 37, 38, 5].

The therapeutic landscape is further evolving with significant advancements in formulation. While injectable forms, offering varying dosing frequencies from daily to weekly, remain highly effective, the advent of oral formulations like oral semaglutide (Rybelsus) and the investigational non-peptide orforglipron signifies a critical stride towards enhanced patient convenience and adherence [46, 48]. These oral options promise to broaden accessibility and potentially increase the uptake of GLP-1-based therapies, overcoming the historical barrier of injectability.

From a safety perspective, GLP-1 receptor agonists are generally well-tolerated. Common gastrointestinal adverse events are typically transient and manageable through gradual dose escalation. Long-term safety data from extensive clinical programs have largely allayed concerns regarding rare but serious events such as pancreatitis and thyroid C-cell tumors, though vigilance remains prudent for specific patient populations [55, 60].

Beyond their established indications, the frontier of GLP-1 receptor agonist research is continuously expanding. Promising preliminary data and ongoing large-scale trials suggest their potential utility in non-alcoholic fatty liver disease (NAFLD/NASH), polycystic ovary syndrome (PCOS), various addiction disorders, and even neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases, along with heart failure with preserved ejection fraction (HFpEF) [69, 73, 76, 80, 82]. These emerging applications underscore the vast therapeutic potential yet to be fully realized for this versatile drug class.

The pharmaceutical market for GLP-1 receptor agonists is characterized by intense competition, predominantly between Novo Nordisk and Eli Lilly, driving innovation in next-generation molecules (e.g., dual/triple agonists) and novel delivery methods [83]. However, the high cost of these therapies remains a significant barrier to widespread access, prompting ongoing discussions about pricing, reimbursement, and equitable availability across diverse healthcare systems [86]. Furthermore, managing the unprecedented global demand and ensuring robust supply chains represent critical challenges for manufacturers.

In conclusion, GLP-1 receptor agonists are not merely glucose-lowering agents but comprehensive metabolic modulators with profound and sustained effects on weight, cardiovascular health, and renal outcomes. Their continued development, evolving formulations, and expanding indications solidify their position as indispensable tools in the armamentarium against the pervasive challenges of T2DM, obesity, and their myriad complications. A thorough understanding of their mechanisms, therapeutic spectrum, safety considerations, and market dynamics is paramount for optimizing their judicious and impactful application in clinical practice, ultimately improving patient outcomes and public health on a global scale.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S44.
2. World Health Organization. Obesity and overweight. [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. [Accessed 2024, May 28].
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
4. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102.
5. Novo Nordisk. Semaglutide slows kidney disease progression in people with type 2 diabetes and chronic kidney disease. Press Release. [Online]. Available from: https://www.novonordisk.com/news-and-media/news-and-articles/news-root/2024/03/semaglutide-slows-kidney-disease-progression.html. [Accessed 2024, May 28].
6. Financial Times. The race to create the next blockbuster obesity drug. [Online]. Available from: https://www.ft.com/content/0d947b51-b46d-4482-a6fe-6c1ccf9388e0. [Accessed 2024, May 28].
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
8. Meier JJ. GLP-1 receptor agonists for the treatment of type 2 diabetes: a look into the future. Diabetes Care. 2012;35(Suppl 2):S169-S173.
9. Richter G, Göke R, Göke B. The glucagon-like peptide 1 (GLP-1) receptor: molecular and pharmacological aspects. Pharmacol Rev. 1993;45(3):357-386.
10. Bregenholt S, et al. GLP-1 receptor signalling: current perspectives on the therapeutic potential of GLP-1 receptor agonists. Curr Pharm Des. 2013;19(39):6818-6828.
11. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.
12. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res. 2003;58:341-369.
13. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology and therapeutic implications. Diabetes Obes Metab. 2016;18(Suppl 1):5-19.
14. Gribble FM, Reimann F. Enteroendocrine L-cells: the enigmatic producers of GLP-1, GIP, and PYY. Vitam Horm. 2019;109:47-72.
15. D’Alessio DA. The Incretin System as a Target for Diabetes Therapy. J Clin Invest. 2011;121(7):2548-2551.
16. Wang M, et al. GLP-1 inhibits glucagon secretion via the somatostatin pathway in human pancreatic α-cells. Diabetologia. 2022;65(3):578-591.
17. Stevens JE, et al. The effect of liraglutide on gastric emptying and energy intake in obese subjects. Br J Pharmacol. 2017;174(24):4601-4610.
18. Hveem K, et al. The effect of liraglutide on gastric emptying, appetite, and energy intake in healthy obese subjects. Diabetologia. 2017;60(10):1916-1923.
19. Glimcher PW, Druker MJ. The role of GLP-1 in the regulation of appetite and energy balance. Trends Pharmacol Sci. 2012;33(5):269-276.
20. Ryan KK, et al. The CNS GLP-1 receptor: a metabolic master switch. Endocrinology. 2012;153(1):15-20.
21. Trapp S, et al. The brain distribution of peripheral GLP-1 is not limited to circumventricular organs. J Neurosci. 2011;31(15):5724-5732.
22. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.
23. Monami M, et al. GLP-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. 2017;123:33-40.
24. Li X, et al. GLP-1 receptor agonists improve metabolic profile and reduce inflammation in patients with type 2 diabetes. J Diabetes Res. 2017;2017:8502573.
25. Sokolońska M, et al. Cardioprotective effects of GLP-1 receptor agonists. Int J Mol Sci. 2021;22(14):7390.
26. Mann JFE, et al. Effects of semaglutide on kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A post-hoc analysis of the SUSTAIN-6 trial. Kidney Int. 2019;95(2):406-413.
27. Zhao H, et al. GLP-1 receptor agonists and kidney protection in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2018;2018:7862145.
28. Holscher C. Targeting the GLP-1 receptor for neuroprotection. Biomed Res Int. 2018;2018:1620610.
29. Sumida Y, et al. Efficacy and safety of GLP-1 receptor agonists in non-alcoholic fatty liver disease. J Clin Med. 2021;10(11):2345.
30. Wilding JPH, et al. Weight loss with once-weekly semaglutide in adults with obesity. N Engl J Med. 2021;384(11):989-1002.
31. Wilding JPH, et al. Once-weekly semaglutide in adults with obesity or overweight. N Engl J Med. 2021;384(11):989-1002.
32. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
33. Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
34. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. (LEADER Study)
35. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. (SUSTAIN-6 Study)
36. Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;381(9):842-851. (PIONEER 6 Study)
37. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. (REWIND Study)
38. Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-1239. (EXSCEL Study)
39. Packer M, et al. The GLP-1 receptor agonists: a new class of agents for the treatment of cardiovascular disease. Eur Heart J. 2017;38(32):2478-2486.
40. Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1961.
41. Alicic RZ, et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045.
42. Buse JB, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9865):367-375.
43. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
44. Tahrani AA, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(6):441-450.
45. Novo Nordisk. Rybelsus (semaglutide) prescribing information. [Online]. Available from: https://www.rybelsus.com/content/dam/rybelsus/rybelsus-pi.pdf. [Accessed 2024, May 28].
46. Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;381(9):842-851. (PIONEER 6 Study)
47. Eli Lilly and Company. Eli Lilly announces Phase 2 data for oral GLP-1 receptor agonist orforglipron. Press Release. [Online]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-announces-phase-2-data-oral-glp-1-receptor-agonist. [Accessed 2024, May 28].
48. Pillay J, et al. Once-daily oral orforglipron for overweight and obesity: A phase 2 dose-finding trial. The Lancet. 2023;401(10390):1825-1837.
49. Frias JP, et al. Efficacy and safety of orforglipron once daily in patients with type 2 diabetes: a randomized, dose-finding, phase 2 trial. Lancet. 2023;401(10390):1811-1824.
50. Whalen KL, et al. Oral GLP-1 receptor agonists: the new frontier in type 2 diabetes management. J Clin Pharm Ther. 2023;48(1):15-28.
51. FDA. GLP-1 Receptor Agonists Information. [Online]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-identifies-potential-safety-issues-glp-1-receptor-agonists. [Accessed 2024, May 28].
52. Buse JB, et al. 2021 Update to the American Diabetes Association’s Standards of Medical Care in Diabetes. Diabetes Care. 2021;44(Suppl 1):S1-S21.
53. Nauck MA. Incretin-based therapies for type 2 diabetes: Gaining momentum. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):123-131.
54. Monami M, et al. Glucagon-like peptide-1 receptor agonists and acute pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Care. 2014;37(4):1127-1134.
55. Drucker DJ, et al. No evidence of increased risk of acute pancreatitis with GLP-1 receptor agonists in clinical trials. Lancet Diabetes Endocrinol. 2013;1(1):26-30.
56. Dicembrino F, et al. GLP-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Endocrine. 2013;43(3):561-568.
57. FDA. Highlights of Prescribing Information for GLP-1 receptor agonists. [Online]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206952s000lbl.pdf. [Accessed 2024, May 28].
58. Gribble FM, Reimann F. Enteroendocrine L-cells: the enigmatic producers of GLP-1, GIP, and PYY. Vitam Horm. 2019;109:47-72.
59. Nauck MA, et al. Pancreatitis and thyroid cancer with GLP-1-based drugs: a review of the evidence. Diabetologia. 2014;57(5):856-869.
60. American Thyroid Association. Statement on GLP-1 receptor agonists and medullary thyroid carcinoma risk. [Online]. Available from: https://www.thyroid.org/glp-1-receptor-agonists-and-medullary-thyroid-carcinoma-risk/. [Accessed 2024, May 28].
61. Betz D, et al. Review of diabetic retinopathy in GLP-1 receptor agonist clinical trials. Ophthalmology. 2020;127(3):365-374.
62. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. 2021.
63. Ferris FL, et al. Rapid progression of diabetic retinopathy in patients with type 2 diabetes undergoing intensive glucose lowering: an analysis from the ACCORD Eye Study. Arch Ophthalmol. 2012;130(9):1153-1158.
64. He L, et al. Risk of acute gallbladder disease associated with GLP-1 receptor agonists: a meta-analysis of randomized controlled trials. J Diabetes. 2018;10(12):922-930.
65. Nauck MA, et al. Hypoglycemia risk during GLP-1 receptor agonist therapy. Curr Diab Rep. 2018;18(1):3.
66. Eslam M, et al. The new definition of fatty liver disease: an international consensus statement. J Hepatol. 2020;73(1):202-208.
67. Harrison SA, et al. Semaglutide for the treatment of nonalcoholic steatohepatitis: A multicenter, randomized, placebo-controlled phase 2 study. Lancet Gastroenterol Hepatol. 2018;3(4):224-234.
68. Newsome PN, et al. A placebo-controlled, randomized trial of semaglutide in patients with nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.
69. Legro RS. Obesity and PCOS: the effect of GLP-1 receptor agonists. Endocrine. 2017;55(1):78-86.
70. Jensterle M, et al. The use of GLP-1 receptor agonists in polycystic ovary syndrome. Endocrine. 2015;48(3):792-799.
71. Andersen M, et al. Liraglutide effects on insulin sensitivity in women with polycystic ovary syndrome. Eur J Endocrinol. 2016;174(1):31-39.
72. Jensterle M, et al. Liraglutide as a treatment for women with PCOS and obesity. Expert Rev Endocrinol Metab. 2019;14(1):15-21.
73. Vallon-Roche J, et al. GLP-1 receptor agonists: a potential new approach for the treatment of addiction. Neuropsychopharmacology. 2022;47(1):198-208.
74. Erreger K, et al. GLP-1 receptor signaling in the brain: implications for obesity and beyond. Trends Neurosci. 2013;36(1):1-8.
75. Nogueiras R, et al. Glucagon-like peptide-1 receptor agonists and their role in the treatment of addiction. Trends Pharmacol Sci. 2023;44(2):107-122.
76. Holscher C. GLP-1 mimetics as a treatment for Alzheimer’s and Parkinson’s diseases. Expert Rev Neurother. 2013;13(9):1081-1099.
77. Femminella GD, et al. A review of the putative links between GLP-1 and neurodegeneration. J Diabetes Res. 2019;2019:8614138.
78. Hölscher C. Novel application of GLP-1 mimetics for the treatment of Alzheimer’s and Parkinson’s diseases. J Alzheimers Dis. 2018;64(Suppl 1):S499-S509.
79. Edison P, et al. Semaglutide for cognitive impairment in early Alzheimer’s disease: the REWIND-AD study. Alzheimers Dement. 2023;19(S18):e078923.
80. Shah SJ, et al. Heart Failure With Preserved Ejection Fraction. Circulation. 2017;135(21):e997-e1017.
81. Kosiborod MN, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1081. (STEP-HFpEF Trial)
82. GlobalData. Global GLP-1 Receptor Agonists Market – Analysis and Forecast (2020-2030). [Online]. Available from: https://www.globaldata.com/store/report/glp-1-receptor-agonists-market-analysis/. [Accessed 2024, May 28].
83. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
84. Nauck MA, et al. Evolving the Incretin Concept: GLP-1 and GIP Co-Agonists. Handb Exp Pharmacol. 2022;277:247-270.
85. Cohen H. Paying for new drugs: The challenges of pricing, reimbursement, and patient access. J Clin Pharmacol. 2019;59(Suppl 3):S1-S12.
86. CNN Health. Ozempic and Wegovy shortages are expected to continue this year, FDA says. [Online]. Available from: https://edition.cnn.com/2024/02/09/health/ozempic-wegovy-shortages-fda/index.html. [Accessed 2024, May 28].
87. American Medical Association. AMA policy for drug costs and pricing. [Online]. Available from: https://www.ama-assn.org/press-center/press-releases/ama-takes-new-action-address-high-drug-costs. [Accessed 2024, May 28].